IgGenix, a San Francisco-based biotech company, announced yesterday they had secured $40 million in Series B funding to bring a peanut allergy candidate to...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
“In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune’s global leadership in the evolving therapeutic landscape of food allergy treatments.”